摘要
目的接受放疗和化疗的患者发生放化疗相关性腹泻的风险很高,然而奥曲肽在控制放化疗相关性腹泻有效性上仍存在争议。本研究对相关随机对照试验(randomized controlled trials,RCTs)进行了荟萃分析,以评估奥曲肽治疗放化疗相关性腹泻的有效性。方法通过计算机全面检测PubMed、Web of Science、The Cochrane Library、Medline、中国知网、万方和维普等数据库中,公开发表的关于奥曲肽治疗放化疗相关腹泻有效性的文章,检索截止时间为2019-06,提取相关数据后经ReaMan 5.3软件进行Meta分析,并遵循系统综述和Meta分析优先报告条目(Preferred Reporting Items for Systematic Reviews and Meta-Analyses,PRISMA)进行。结果最终纳入9项试验,共612例肿瘤患者。Meta分析结果显示,奥曲肽在治疗放化疗相关性腹泻上更有效果,差异有统计学意义,OR=4.99,95%CI为2.11~11.80,P<0.001;另外奥曲肽在缓解放化疗相关性腹泻时间上更快,OR24h=16.02,95%CI为3.51~73.15,P<0.001;OR48h=4.70,95%CI为1.65~13.42,P=0.004;OR96h=14.49,95%CI为6.24~33.65,P<0.001。结论奥曲肽能够在短时间内更有效地控制放化疗相关性腹泻。
OBJECTIVE Patients receiving radiotherapy and chemotherapy have a high risk of chemoradiotherapyinduced diarrhea,but octreotide remains controversial in controlling the efficacy of chemoradiotherapy-induced diarrhea.This study conducted a meta-analysis of randomized controlled trials(RCTs)to evaluate the efficacy of octreotide in the treatment of chemoradiotherapy-induced diarrhea.METHODS Through the computer to comprehensively detect the PubMed,Web of Science,The Cochrane Library,Medline,China National Knowledge Infrastructure,Wanfang and VIP databases,published articles on the effectiveness of octreotide in chemoradiotherapy-induced diarrhea,the search deadline is2019-06.The relevant data was extracted and subjected to meta-analysis by ReaMan 5.3 software,and was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses(PRISMA).RESULTS Meta-analysis showed that octreotide was more effective in the treatment of chemoradiotherapy-induced diarrhea,the difference was statistically significant,OR=4.99,95%CI:2.11-11.80,P<0.001;in addition,octreotide was relieved of chemoradiotherapy-induced diarrhea time Faster,OR24 h=16.02,95%CI:3.51-73.15,P<0.001;OR48 h=4.70,95%CI:1.65-13.42,P=0.004;OR96 h=14.49,95%CI:6.24-33.65,P<0.001.CONCLUSION Octreotide can more effectively control chemoradiotherapy-induced diarrhea in a short period of time.
作者
马德健
曹珍
王贲士
孙燕来
MA De-jian;CAO Zhen;WANG Bi-shi;SUN Yan-lai(School of Medicine and Life Sciences,University of Jinan-Shandong Academy of Medical Sciences,Jinan 250200,P.R.China;Department of Gastrointestinal Cancer Surgery,Shandong Cancer Hospital and Institute,Shandong First Medical University and Shandong Academy of Medical Sciences,Jinan 250117,P.R.China)
出处
《中华肿瘤防治杂志》
CAS
北大核心
2020年第2期146-151,共6页
Chinese Journal of Cancer Prevention and Treatment
基金
济南临床医学科技创新计划（201805091）
中国博士后科学基金（2017M612317）
